- Kumquat to lead research and clinical development into Phase
1
- Kumquat has an option to co-develop and share in U.S. for
profit/loss
SAN
DIEGO, April 16, 2024 /PRNewswire/ -- Kumquat
Biosciences, a leader in translating breakthrough science into
first-in-class therapeutics, announced today a strategic and
exclusive collaboration with Takeda to develop and
commercialize a novel immuno-oncology small molecule inhibitor as a
mono- and/or combination-therapy.
Under the terms of the agreement, Kumquat granted
Takeda an exclusive, global, and royalty bearing license to develop
and commercialize a selected small molecule inhibitor. Subject to
Kumquat's option, Takeda will assume and fund all development and
commercialization activities beyond the phase 1 trial activities
led by Kumquat. Kumquat will receive up to $130 million in near-term payments and
potentially more than $1.2 billion if
all future clinical, regulatory, and commercial milestones are
achieved during the term of the agreement plus tiered royalties on
potential net sales of any commercial products resulting from this
license.
"The advancement of this immuno-oncology small
molecule program speaks to our ability to thrive on the challenges
of drugging tough therapeutic targets of great potential," said
Yi Liu, Chief Executive Officer of
Kumquat. "We are proud of our persistent and innovative
breakthrough, and we are thrilled to collaborate with Takeda, who
shares our vision and strategy for realizing the benefit of small
molecule-based transformative I/O treatments. This collaboration
empowers this I/O program to advance to the clinic quickly and
holds potential to benefit a broad population of cancer patients."
"We are excited to collaborate with Kumquat, an
accomplished team with deep insights into this challenging target
and therapeutic space," said P.K. Morrow, the Head of the Oncology
Therapeutic Area Unit at Takeda. "This collaboration aligns with
our mission to advance a cutting-edge pipeline focused on
maximizing the benefit of the immune system to address the
continued unmet needs of cancer patients. We look forward to
working with Kumquat to accelerate the development of this exciting
asset."
About Kumquat Biosciences
Kumquat
Biosciences is a privately held drug discovery and development
company committed to creating breakthrough medicines for the
treatment of cancer. The company focuses on translating
breakthrough science into first-in-class and best-in-class
therapeutics. Kumquat brings together an accomplished team and
distinguished scientific founder with a proven track record of
innovative oncology drug discovery and development. The company was
launched in 2019 and funded by OrbiMed, Hongshan (formerly Sequoia
Capital, China), EcoR1, Lilly Asia
Ventures, and Roche Venture Fund, as well as through corporate
partnerships. For more information, please visit
www.kumquatbiosciences.com or refer to PRnews@kumquatbio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kumquat-biosciences-and-takeda-enter-into-strategic-collaboration-and-exclusive-global-license-agreement-to-advance-novel-oral-immuno-oncology-drug-candidate-302117294.html
SOURCE Kumquat Biosciences Inc.